Skip to main content

Table 4 Incidence of adverse drug reactions caused by prophylactic trimethoprim–sulfamethoxazole

From: Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole

  Number of casesa Incidence rate (95% CI)b
Mild-to-moderate adverse drug reactions 11 30.7 (15.3–55.0)
 Anemia 1 2.8 (0.1–15.6)
 Thrombocytopenia 2 5.6 (0.7–20.2)
 LFT abnormality 3 8.4 (1.7–24.5)
 Skin rash 2 5.6 (0.7–20.2)
 Azotemia 1 2.8 (0.1–15.6)
 Othersc 2 5.6 (0.7–20.2)
Serious adverse drug reactionsd 1 2.8 (0.1–15.6)
 Pancytopeniad 1 2.8 (0.1–15.6)
 Stevens–Johnson syndrome 0 NA
  1. CI confidence interval, LFT liver function test, NA non-applicable
  2. aTotal observation period was 31.0 person-years for 45 episodes
  3. bRate per 100 person-years
  4. cIncluding headache (n = 1) and tingling sensation (n = 1)
  5. dOccurred in the non-high-risk subgroup
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us